Evidence map›Paper›PMID 25596079›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2015

Analysis of human innate immune responses to PRINT fabricated nanoparticles with cross validation using a humanized mouse model.

Gregory R Robbins, Reid A Roberts, Haitao Guo, Kevin Reuter, Tammy Shen, Gregory D Sempowski, Karen P McKinnon, Lishan Su, Joseph M DeSimone, Jenny P-Y Ting

Open access · greenAbstract read
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Gregory R RobbinsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Reid A RobertsDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Haitao GuoDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kevin ReuterDepartment of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Tammy ShenDepartment of Pharmaceutical Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Gregory D SempowskiDuke Human Vaccine Institute, Duke University Medical Center, Durham, NC, USA.
Karen P McKinnonDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Lishan SuDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Joseph M DeSimoneLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Pharmaceutical Sciences, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Department of Chemical and Biomolecular Engineering, NC State University, Raleigh, NC, USA; Sloan-Kettering Institute for Cancer Research, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Jenny P-Y TingDepartment of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA; Center for Translational Immunology and Institute of Inflammatory Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. Electronic address: jenny_ting@med.unc.edu.
University of North Carolina at Chapel Hill · USDuke Medical Center · USMemorial Sloan Kettering Cancer Center · US

Funding

Protein Expression/Dengue Virology CoreU19AI109784 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TING, JENNY P · 2014 to 2018
$20.8M
Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM008719 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DARVILLE, TONI, DESHMUKH, MOHANISH P · 1999 to 2023
$15.1M
BASIC IMMUNE MECHANISMST32AI007273 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TISCH, ROLAND M · 1985 to 2020
$5.6M
HIV co-infection and HCV-induced liver fibrosis in vivoR01AI095097 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2012 to 2016
$1.8M
HIV-1 Replication and Pathogenesis in vivoR01AI080432 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI SU, LISHAN · 2009 to 2012
$1.4M
Delivery of Biological Therapeutics: Using Engineered Particles and Novel DeliverDP1CA174425 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESIMONE, JOSEPH M. · 2012 to 2013
$1.4M
NCI NIH HHS 8-VP1-CA174425-04NCI NIH HHS DP1 CA174425NCI NIH HHS T32 CA009156NCI NIH HHS T-32-CA009156-37NIAID NIH HHS AI080432NIAID NIH HHS R01 AI080432NIAID NIH HHS R01 AI095097NIAID NIH HHS R01AI095097NIAID NIH HHS T32 AI007273NIAID NIH HHS T32-AI007273-25NIAID NIH HHS U19 AI109784NIAID NIH HHS U19AI109784NIAID NIH HHS UC6 AI058607NIAID NIH HHS UC6-AI058607NIGMS NIH HHS T-32-GM008719NIGMS NIH HHS T32 GM008719PHS HHS 1F32A1108159-01
6 · The paper itself

Abstract

Ideal nanoparticle (NP)-based drug and vaccine delivery vectors should be free of inherent cytotoxic or immunostimulatory properties. Therefore, determining baseline immune responses to nanomaterials is of utmost importance when designing human therapeutics. We characterized the response of human immune cells to hydrogel NPs fabricated using Particle Replication in Non-wetting Templates (PRINT) technology. We found preferential NP uptake by primary CD14(+) monocytes, which was significantly reduced upon PEGylation of the NP surface. Multiplex cytokine analysis of NP treated primary human peripheral blood mononuclear cells suggests that PRINT based hydrogel NPs do not evoke significant inflammatory responses nor induce cytotoxicity or complement activation. We furthered these studies using an in vivo humanized mouse model and similarly found preferential NP uptake by human CD14(+) monocytes without systemic inflammatory cytokine responses. These studies suggest that PRINT hydrogel particles form a desirable platform for vaccine and drug delivery as they neither induce inflammation nor toxicity. From the clinical editor: The authors here fabricated hydrogel nanorods using the PRINT (Particle Replication In Nonwetting Templates) fabrication process. They tested the interaction of human immune cells with these particles and found no immunoreactivity. This finding would suggest that monodisperse PRINT particles of identical shape and size could serve a variety of clinical applications.

Indexed as

Drug Delivery SystemsImmunity, InnateAnimalsCell Line, TumorCytokinesDrug Evaluation, PreclinicalHumansImmunizationLipopolysaccharide ReceptorsMiceMice, Inbred NODMice, KnockoutMonocytesNanoparticlesVaccinesCytokinesLipopolysaccharide ReceptorsVaccinesComplementHumanized miceMonocytesNanoparticlesPEGylationPRINTToxicity

Identifiers

PMID25596079
PMCPMC4385431
OpenAlexW2170600342

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.